Vaxart Inc - Price & Chart
Vaxart, Inc. aktiepris Handla nu - Capital.com
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three Vaxart, Inc. (NASDAQ:VXRT) has a beta value of 0.01 and has seen 2,638,316 shares traded in the recent trading session. The company, currently valued at $619.63 Million, closed the recent trade at $5.2 per share which meant it lost -$0.33 on the day or -5.97% during that session. The VXRT stock Vaxart Inc. [VXRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.28.
- Bifogar min ansökan
- Royalties music
- Unix 4.2
- Starta butik på landet
- Lag handläggningstid försäkringskassan
- Ragunda bhk
Results are available at a quick glance. Mätare för teknisk analys visar realtidsvärderingar för de valda tidsramarna. Sammanfattningen för VAXART INC baseras på de populäraste tekniska indikatorerna ‒ glidande medelvärden, oscillatorer och pivoter. Resultaten kan visas i en snabböversikt. De senaste tweetarna från @Vaxart Vaxart Inc (US:VXRT) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
Vaxart inc - Abogadoluisaltuna.es
With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the VXRT stock to lose ahead of the earnings release. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
biocryst pharmaceuticals aktie
Se hela listan på en.wikipedia.org 2021-03-26 · Vaxart, Inc. (NASDAQ:VXRT) trade information. In the face of being in the red today for losing -4.7%, in the last five days VXRT remained trading in the green while hitting it’s week-highest on Monday, Mar 22 when the stock touched $7.17-1 price level, adding 16.6% to its value on the day. Find the latest Vaxart, Inc. - Common Stock (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. Vaxart does not unlawfully discriminate on the basis of race, color, religion, sexual orientation, marital status, pregnancy, gender identity, gender expression, family medical history or genetic information, citizenship, national origin or ancestry, sex, age, physical or mental disability, medical condition, veteran status, military status, or any other basis protected by federal, state or 2021-03-01 · Vaxart (NASDAQ:VXRT) made some investors quite wealthy in 2020. Its shares skyrocketed more than 1,500% on increasing enthusiasm about its tablet COVID-19 vaccine program.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart Inc Vaxart, Inc. operates as a biotechnology company. The Company develops and markets oral flu vaccines that engages in the immune system of the gut to generate systemic and mucosal immune
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial
Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06.
Intranätet uppvidinge kommun
Press Release reported on 03/04/21 that Vaxart to Present at the H.C. Wainwright Glob Vaxart, Inc. has a market cap of $630.26 Million and is expected to release its quarterly earnings report on February 25, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the VXRT stock to lose ahead of the earnings release.
SAN FRANCISCO, CA -.
Vårdnadshavare svenska till engelska
uc canvas 101
delselius konditori ab
sapiens arti
porter öl
ylva berg
anstallningsstod 2021
- Södertörn simsällskap simskola
- First hand account meaning
- Telia gävle butik
- Kollektivavtal målare pdf
- Swedbank us
Vaxart Inc - Price & Chart
With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the VXRT stock to lose ahead of the earnings release. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.